首页> 外文期刊>American Journal of Nuclear Medicine and Molecular Imaging >Added value of cost-utility analysis in simple diagnostic studies of accuracy: 18F-fluoromethylcholine PET/CT in prostate cancer staging
【24h】

Added value of cost-utility analysis in simple diagnostic studies of accuracy: 18F-fluoromethylcholine PET/CT in prostate cancer staging

机译:成本-效用分析在准确性的简单诊断研究中的附加值:18F-氟甲基胆碱PET / CT在前列腺癌分期中的应用

获取原文
           

摘要

Diagnostic studies of accuracy targeting sensitivity and specificity are commonly done in a paired design in which all modalities are applied in each patient, whereas cost-effectiveness and cost-utility analyses are usually assessed either directly alongside to or indirectly by means of stochastic modeling based on larger randomized controlled trials (RCTs). However the conduct of RCTs is hampered in an environment such as ours, in which technology is rapidly evolving. As such, there is a relatively limited number of RCTs. Therefore, we investigated as to which extent paired diagnostic studies of accuracy can be also used to shed light on economic implications when considering a new diagnostic test. We propose a simple decision tree model-based cost-utility analysis of a diagnostic test when compared to the current standard procedure and exemplify this approach with published data from lymph node staging of prostate cancer. Average procedure costs were taken from the Danish Diagnosis Related Groups Tariff in 2013 and life expectancy was estimated for an ideal 60 year old patient based on prostate cancer stage and prostatectomy or radiation and chemotherapy. Quality-adjusted life-years (QALYs) were deduced from the literature, and an incremental cost-effectiveness ratio (ICER) was used to compare lymph node dissection with respective histopathological examination (reference standard) and sup18/supF-fluoromethylcholine positron emission tomography/computed tomography (FCH-PET/CT). Lower bounds of sensitivity and specificity of FCH-PET/CT were established at which the replacement of the reference standard by FCH-PET/CT comes with a trade-off between worse effectiveness and lower costs. Compared to the reference standard in a diagnostic accuracy study, any imperfections in accuracy of a diagnostic test imply that replacing the reference standard generates a loss in effectiveness and utility. We conclude that diagnostic studies of accuracy can be put to a more extensive use, over and above a mere indication of sensitivity and specificity of an imaging test, and that health economic considerations should be undertaken when planning a prospective diagnostic accuracy study. These endeavors will prove especially fruitful when comparing several imaging techniques with one another, or the same imaging technique using different tracers, with an independent reference standard for the evaluation of results.
机译:通常在成对设计中对准确性靶向敏感性和特异性进行诊断研究,在这种设计中,所有患者均应采用所有方法,而成本效益和成本效用分析通常直接或间接地基于以下因素进行评估:较大的随机对照试验(RCT)。但是,RCT的行为在诸如我们这样的技术飞速发展的环境中受到阻碍。因此,RCT的数量相对有限。因此,我们研究了在考虑使用新的诊断测试时,在多大程度上还可以使用准确性的配对诊断研究来阐明经济意义。当与当前的标准程序进行比较时,我们提出了一种基于简单决策树模型的诊断测试的成本-效用分析,并以前列腺癌淋巴结分期的已发表数据为例来说明这种方法。平均手术费用取自2013年丹麦诊断相关小组的关税,根据前列腺癌分期,前列腺切除术或放疗和化疗,估算了理想的60岁患者的预期寿命。从文献中推算出质量调整生命年(QALYs),并使用增量成本效益比(ICER)将淋巴结清扫与相应的组织病理学检查(参考标准)和 18 F进行比较-氟甲基胆碱正电子发射断层扫描/计算机断层扫描(FCH-PET / CT)。确定了FCH-PET / CT的敏感性和特异性的下限,在这种情况下,用FCH-PET / CT代替参考标准品需要在效果较差和成本较低之间进行权衡。与诊断准确性研究中的参考标准相比,诊断测试准确性的任何缺陷都意味着替换参考标准会导致有效性和实用性下降。我们得出的结论是,准确性的诊断研究可以被广泛应用,而不仅仅是影像学检查的敏感性和特异性的指示,并且在计划进行前瞻性诊断准确性研究时应考虑健康的经济因素。当将几种成像技术或使用不同示踪剂的同一成像技术进行比较,并使用独立的参考标准评估结果时,这些努力将证明是卓有成效的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号